MoonLake Immunotherapeutics Sees Unusually Large Options Volume (NASDAQ:MLTX)

MoonLake Immunotherapeutics (NASDAQ:MLTX) was the recipient of some unusual options trading activity on Monday. Stock traders acquired 18,262 call options on the company. This is an increase of 869% compared to the typical daily volume of 1,884 call options.

Institutional Trading of MoonLake Immunotherapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Deutsche Bank AG grew its position in MoonLake Immunotherapeutics by 59.8% during the 4th quarter. Deutsche Bank AG now owns 903 shares of the company’s stock worth $49,000 after acquiring an additional 338 shares during the last quarter. Elevation Point Wealth Partners LLC bought a new position in shares of MoonLake Immunotherapeutics in the second quarter worth approximately $74,000. US Bancorp DE increased its stake in shares of MoonLake Immunotherapeutics by 114.4% in the first quarter. US Bancorp DE now owns 2,208 shares of the company’s stock worth $86,000 after buying an additional 1,178 shares during the period. Quarry LP bought a new stake in MoonLake Immunotherapeutics during the 1st quarter valued at $94,000. Finally, Advisors Asset Management Inc. boosted its position in MoonLake Immunotherapeutics by 81.7% during the 1st quarter. Advisors Asset Management Inc. now owns 4,009 shares of the company’s stock valued at $157,000 after buying an additional 1,803 shares during the period. 93.85% of the stock is currently owned by hedge funds and other institutional investors.

MoonLake Immunotherapeutics Trading Down 89.9%

Shares of MoonLake Immunotherapeutics stock opened at $6.24 on Tuesday. The company’s 50-day moving average price is $53.73 and its 200-day moving average price is $46.01. The company has a current ratio of 16.65, a quick ratio of 16.65 and a debt-to-equity ratio of 0.21. MoonLake Immunotherapeutics has a 12-month low of $5.95 and a 12-month high of $62.75. The company has a market cap of $400.80 million, a price-to-earnings ratio of -2.24 and a beta of 1.27.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.14). During the same quarter in the prior year, the firm earned ($0.39) EPS. On average, equities analysts expect that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on MLTX. Rothschild & Co Redburn started coverage on MoonLake Immunotherapeutics in a report on Monday, July 28th. They issued a “neutral” rating and a $65.00 target price on the stock. Stifel Nicolaus downgraded MoonLake Immunotherapeutics from a “buy” rating to a “hold” rating and set a $13.00 price objective for the company. in a research note on Monday. Redburn Atlantic upgraded MoonLake Immunotherapeutics to a “hold” rating in a research note on Monday, July 28th. BTIG Research downgraded shares of MoonLake Immunotherapeutics from a “buy” rating to a “neutral” rating and set a $85.00 price target on the stock. in a report on Monday. Finally, Royal Bank Of Canada restated a “sector perform” rating and set a $10.00 price target (down previously from $67.00) on shares of MoonLake Immunotherapeutics in a research report on Monday. Five analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $57.00.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.